Communiqués XLIE SCIE OTC Markets

Actions

XLSCF

CH0461929603

Recherche biotechnologique et médicale

Temps Différé OTC Markets			Varia. 5j.	Varia. 1 janv.
- ^USD	-.--%		-.--%	-

08:20	Xlife Sciences AG publie ses résultats pour le semestre clos le 30 juin 2026	CI
08:01	Xlife Sciences a vu son chiffre d'affaires semestriel s'enrober	AW

Communiqués

30/04	Xlife Sciences : Investor Presentation (429 Xlife Sciences AG IR Presentation)	PU
28/04	Xlife Sciences : Investor Presentation (422 Xlife Sciences AG IR Presentation)	PU
28/04	Xlife Sciences AG publishes 2025 Annual Report: Strategic positioning and preparation of key capital market transactions	PU
22/04	Xlife Sciences : Praesentation	PU
03/03	VERAXA Biotech Receives 99.57% Approval for Merger - Path to NASDAQ Listing Under «VRXA» Cleared	EQ
27/01	Xlife Sciences : Praesentation	PU
31/12	Update on Ongoing Transactions with Pharmaceutical Company Grupo Landsteiner and the NASDAQ Listing of VERAXA Biotech AG	EQ
23/12	Xlife Sciences AG Announces Transition to the Main Segment of SIX Swiss Exchange to Strengthen Market Presence	EQ
12/12	Award-Winning Liver PET Tracer Highlights the Strength of Our Innovation Portfolio	EQ
08/12	Xlife Sciences AG Announces Exit of 12 Project Companies to Grupo Landsteiner and the Creation of a Scalable Transcontinental Life Sciences Platform	EQ
01/12	Xlife Sciences AG Delivers Breakthrough in Early Alzheimer’s Detection, Unlocking Major Market Opportunity	EQ
28/11	Xlife Sciences AG Provides Update on VERAXA Biotech AG’s NASDAQ Listing Process Following U.S. Government Shutdown	EQ
27/10/25	Xlife Sciences : Praesentation	PU
16/10/25	Xlife Sciences AG Publishes 2024 ESG Report: Sustainable Value Creation as a Strategic Core	EQ
08/10/25	Xlife Sciences : Praesentation	PU
23/09/25	Xlife Sciences AG Half-Year Report 2025: Focus on VERAXA Biotech AG’s NASDAQ Listing and Internationalization	EQ
23/09/25	Xlife Sciences AG Half-Year Report 2025: Focus on VERAXA Biotech AG’s NASDAQ Listing and Internationalization	PU
23/09/25	Xlife Sciences : Half-Year Report 2025	PU
17/07/25	Xlife Sciences AG’s Portfolio Company, VERAXA Biotech AG, Takes Key Step Toward NASDAQ Listing with Filing of Form F-4	EQ
02/07/25	Xlife Sciences : Praesentation	PU
24/06/25	Xlife Sciences AG: Successful General Meeting and Growth Prospects for 2025	EQ
16/06/25	Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and OncoMASTER Inc. to Boost Digital Health and Precision Oncology in Asia	EQ
13/06/25	Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Accelerate Korean Life Sciences Ventures’ Access to Global Capital Markets	EQ
09/05/25	Xlife Sciences : Praesentation	PU
06/05/25	Xlife Sciences AG Announces Strategic Collaboration between Portfolio Company Firstgene Life Sciences and Hovione in the Field of Gene Therapy	EQ